No Data
No Data
Pharmaxis Ltd's Aspirations Amidst Uncertainties
Pharmaxis Ltd Advances Clinical Trials, Boosts Savings
Pharmaxis Ltd Announces Major Shareholder Changes
Syntara Receives AU$5.2 Million R&D Tax Rebate
Syntara (ASX:PXS) received a research and development tax incentive worth AU$5.2 million for fiscal 2023. "The R&D tax incentive is a significant source of nondilutive funding for the company's clinic
Here's Why Shareholders Should Examine Pharmaxis Ltd's (ASX:PXS) CEO Compensation Package More Closely
Pharmaxis Doses First Patient in Phase Two Sleep Trial
Pharmaxis (ASX:PXS) dosed the first patient for its phase two trial investigating the use of the medicinal candidate PXS-4728 in individuals afflicted with Rapid Eye Movement Sleep Behavior Disorder w
No Data